Does Sage Therapeutics ' Failure Predict Its Future Results?
There were amazing stories of brexanolone helping patients with a rare form of epilepsy. But a randomized clinical trial today showed that the drug performed no better than a control group. Shares in its maker, Sage Therapeutics are down 15%.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Source Type: news